Ridinger proposed as DSM-Firmenich Chairman amid Leysen’s retirement

Mason Carter 08/20/2026

New Chapter for DSM-Firmenich: Board Seeks Next Chapter in Leadership

As major corporate entities navigate the complexities of growth and strategy, leadership transitions often signal a pivotal moment. At DSM-Firmenich, the focus is now shifting from the intricate work of post-merger integration to the exciting phase of execution, underscored by a strategic move to appoint a new Chairman.

The Board of Directors has unanimously put forward an ambitious plan, nominating independent director Richard Ridinger to take the helm as the next Chairman, succeeding Thomas Leysen. This transition marks the end of an era of integration and the beginning of a new trajectory for the group.

Ridinger brings a rich and diverse background to the position. His experience spans critical sectors including pharmaceuticals, home and personal care, and nutrition and health. Crucially, he already possesses existing familiarity with the DSM-Firmenich portfolio, providing an immediate foundation for continuity and strategic alignment.

This shift is perfectly timed as the company moves beyond the initial setup phase. While the integration work continues, DSM-Firmenich is actively pursuing its next set of strategic objectives, focusing on delivering on its ambitious strategy, enhancing margins, and driving the next phase of growth.

The upcoming leadership change is designed to inject fresh energy and specialized knowledge as the organization pivots toward operational focus. Ridinger’s expertise in innovation-led businesses, particularly in personal care, is poised to guide the company through this critical execution phase.

The formal appointment of Richard Ridinger will be put to shareholders at an Extraordinary General Meeting scheduled for October 19, 2026. This timeline allows the company to solidify its current momentum while preparing for the future leadership structure.

Meanwhile, operational momentum remains strong. Key initiatives are already in motion, including the successful nearing completion of the planned sale of the Animal Nutrition and Health business, the establishment of a refreshed Executive Committee, and the continued commitment to margin improvement programs across the group.

This succession plan isn’t just about titles; it’s about ensuring that the strategic vision translates seamlessly into tangible results. By bringing a leader with deep industry knowledge and a focus on innovation, DSM-Firmenich is setting the stage for an energized future of focused growth and sustained success.